Neal S. Chawla

Oncologist and researcher at The Cancer Center of Southern California-Sarcoma Oncology Center.

[Sumanta K. Pal, MD, FASCO @montypal]

Please help us! @Uromigos Team #NorthAmerica struggling a bit. Hate to do this (feels like cheating) but will lean on my friends outside of GU (who all seem to know @tompowles1 & @brian_rini) to like the photo in the post below … @ErikaHamilton9 @fumikochino @hoperugo @VivekSubbiah @aparna1024 @rachnatshroff @ninashah33 @StephenVLiu @chadinabhan @DrJNaidoo

[Lawrence Liu @DrLL_MD]

It’s so surreal that today is my last day of fellowship at @cityofhope. I was so lucky to get to do my heme/onc training here with such clinically and academically gifted cofellows and attending physicians and it’s bittersweet to leave this institution.

[Targeted Oncology @TargetedOnc]

Amandeep Salhotra, MD, discusses how patients with advanced #cGVHD often cycle through multiple approved agents, and describes upcoming clinical trials testing upfront use of these novel agents with corticosteroids in newly diagnosed patients. @cityofhope
https://t.co/NRCvpzDxqi

[Sumanta K. Pal, MD, FASCO @montypal]

So proud of our superstar @cityofhope graduating fellow @AlexisLevee, who has been prolific during her 3 years with us! Looking forward to seeing her continued success as she joins @dradityabardia, @minasedrakmd & the phenomenal #breastcancer team at @UCLAHealth!

[Alan H Bryce @AlanBryce9]

Thanks to @montypal for hosting. And thanks to @Waltstadler5 for his no nonsense insights. I've been learning from him for many years. It's a pleasure to push the cutting edge of cancer care with colleagues like this.

[OncLive.com @OncLive]

In an interview with @AlexisLeVee, she discussed:
🌸 Ongoing phase 3 trials in metastatic #TNBC that are evaluating upfront use of ADCs
🌸 Investigational biomarkers that may predict immunotherapy response
🌸 How these biomarkers could lead to de-escalating treatment approaches

[Sumanta K. Pal, MD, FASCO @montypal]

An amazing joint mtg of @MOASC_Office/@ANCO_News at #ASCO25 bringing together so many friends & colleagues in #oncology from around #California! Was delighted to see the @ASCO #Advocacy Team there, alongside @arkhaki @NikitaBacligMD @ChawlaNeal @omgitsyuliaz @arafflemd @PDZOnc @minasedrakmd

[City of Hope @cityofhope]

#ASCO25: City of Hope’s @montypal breaks down IMmotion010 — a phase 3 #clinicaltrial aiming to uncover the mechanisms behind therapy resistance in patients with localized #kidneycancer.

[Neal S. Chawla @ChawlaNeal]

Another great event by MOASC/ANCO! I look forward to catching up again at the MOASC/ANCO Immuno-Oncology Symposium on Septemeber 6th! https://t.co/0KeCQaSySt

[MOASC @MOASC_Office]

Thank you everyone who joined us for our @ANCO_News @MOASC_Office joint luncheon at #ASCO25! We were so excited to see all the collaborations and relationships forming and had a great time meeting our members in person.

@cityofhope @UCSF @Stanford @CSCancerCenter @UCSDCancer @UCLAHealth @uscnorris @UCIrvine @UCDavisHealth

[City of Hope @cityofhope]

We're proud to be part of — and to serve — the Los Angeles community. Thanks @LaInaMinute for highlighting City of Hope's history of innovation and compassionate care!

[Jun Gong @jgong15]

NCTN AREN1721 rand PhII trial of axi/nivo vs nivo in #TFE3/tRCC (prior IO or axi prohibited) ➡️ closed to low accrual after 15 subjects. Nivo mono w/little activity with 1.8 mos to 10.5 mos w/improved ORR and OS favoring axi/nivo in this rare aggressive subset

#ASCO25
@OncoAlert

[Sumanta K. Pal, MD, FASCO @montypal]

What a wonderful moment - seeing @AlexisLevee get ready to take the stage to claim her @ASCO Young Investigator Award! So proud of all her tremendous accomplishments as a fellow at @cityofhope (she got an excellent foundation from @hmcarthur in residency - her co-mentor on this grant!). Excited for her next stage as a #breastcancer-focused investigator at @UCLAHealth w @dradityabardia.

[Neal S. Chawla @ChawlaNeal]

Thank you to @MOASC_Office and @oncologytube for the opportunity to speak about sarcomas and the challenges patients with sarcomas face!

[Oncology Tube @oncologytube]

Are Sarcoma patients being left behind?

"We still get patients that have not had NGS testing by the time they come to us." - Dr. Neil Chawla, MD

"B7-H3 seems to be widely expressed in osteosarcoma and chondrosarcoma." - Dr. Neil Chawla, MD

ARTICLE: https://t.co/e8JGL3dMJy

#SarcomaAwareness" #NGSRevolution @ChawlaNeal @montypal @MOASC_Office #MOASCSummit @SarcomaOncology

[MOASC @MOASC_Office]

We are incredibly proud of @PDZOnc and all the poster award winners at this year's #MOASCAnnualSummit25!

[koral shah, md @kor_shah]

Completely honored to discuss the global disparities of bladder cancer clinical trial availability with THE @UroDocAsh, President of IBCG 🌎🔬Thank you to @urotoday & mentor @montypal for this opportunity. Check it out! @ReginaBarCar @DVCastro_ @mzugman

[Neal S. Chawla @ChawlaNeal]

@PGrivasMDPhD Thank you as always for your support @PGrivasMDPhD ! Thank you to @MOASC_Office Ashkan Lashkari @montypal and Nichole East for the opportunity to serve on the board and to speak at this great conference!

[Neal S. Chawla @ChawlaNeal]

@PDZOnc @cityofhope @TDorffOnc @montypal @DrRaviSalgia Well deserved! Congratulations!

[Peter Zang @PDZOnc]

So honored to be this year's recipient of the MOASC Cary Presant YIA award! So thankful for the wonderful mentorship at @cityofhope and my mentors who inspire me everyday and whose support made this possible @TDorffOnc @montypal @DrRaviSalgia!

[Joshua Garrett Cohen @JCohenMD]

Wonderful to meet dynamic medical oncologists and colleagues dedicated to optimizing cancer care delivery in southern California at the MOASC annual meeting . Thank you for your leadership @montypal and # Dr
Lashkari @MOASC_Office.

[Sumanta K. Pal, MD, FASCO @montypal]

Brilliant talk from @RoussosTorres @uscnorris, who is doing amazing work in the lab on #breastcancer but brought a phenomenal clinical talk on #immunotherapy for BC that spanned the role of CPIs in #TNBC & other nuanced settings, citing work from @stolaney1 @DanaFarber, @JavierCortesMD @wearemedsir et al.